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Epileptic encephalopathy-causing
mutations in DNM1 impair synaptic
vesicle endocytosis
ABSTRACT
Objective: To elucidate the functional consequences of epileptic encephalopathy–causing de novo
mutations in DNM1 (A177P, K206N, G359A), which encodes a large mechanochemical GTPase
essential for neuronal synaptic vesicle endocytosis.
Methods: HeLa and COS-7 cells transfected withwild-type andmutantDNM1 constructswere used
for transferrin assays, high-content imaging, colocalization studies, Western blotting, and electron
microscopy (EM). EM was also conducted on the brain sections of mice harboring a middle-domain
Dnm1 mutation (Dnm1Ftfl).
Results: We demonstrate that the expression of each mutant protein decreased endocytosis activity
in a dominant-negative manner. One of the G-domain mutations, K206N, decreased protein levels.
The G359Amutation, which occurs in the middle domain, disrupted higher-order DNM1 oligomeriza-
tion. EM of mutant DNM1-transfected HeLa cells and of the Dnm1Ftfl mouse brain revealed vesicle
defects, indicating that the mutations likely interfere with DNM1’s vesicle scission activity.
Conclusion: Together, these data suggest that the dysfunction of vesicle scission during synaptic
vesicle endocytosis can lead to serious early-onset epilepsies. Neurol Genet 2015;1:e4; doi:
10.1212/01.NXG.0000464295.65736.da
GLOSSARY
DAPI 5 4’,6-diamidino-2-phenylindole; EDC 5 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide; EM 5 electron microscopy;
GFP 5 green fluorescent protein; LGS 5 Lennox-Gastaut syndrome; RFP 5 red fluorescent protein; RIPA 5 radioimmuno-
precipitation assay; TBS 5 Tris-buffered saline; WT 5 wild type.
Epileptic encephalopathies are a heterogeneous group of severe childhood neurologic disorders
characterized by epileptic activity accompanied by progressive cognitive, behavioral, and sensory
impairments.1 In this study, we conduct functional analysis on 3 de novo missense mutations in
DNM1 that have been implicated in 2 epileptic encephalopathies: Lennox-Gastaut syndrome
(LGS) and infantile spasms.
Dynamin-1 is a 100-kDa mechanochemical GTPase that is required during receptor-
mediated endocytosis and synaptic vesicle recycling.2,3 DNM1, expressed predominantly in
neurons, localizes to the presynaptic terminal and mediates the uptake of synaptic vesicles.4–7
Its expression is upregulated during postnatal development, accompanying synaptogenesis.4,7,8
DNM1 is organized into 5 domains: a G domain that binds and hydrolyzes GTP, a middle
domain that is involved in oligomerization, a GTPase effector domain, a pleckstrin homology
domain, and a proline-rich domain.9–12 During receptor-mediated endocytosis, dynamin mole-
cules assemble into tetramers that hydrolyze GTP.12,13 Upon GTP hydrolysis, DNM1 undergoes
a conformational change that allows it to pinch vesicles from the membrane.14
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A spontaneous mouse mutation in the mid-
dle domain of Dnm1 (Dnm1Ftfl) causes seiz-
ures and hearing defects.8 The missense
mutation affects dynamin oligomerization
and decreases endocytosis activity. Patch-clamp
recordings demonstrate defects in GABAergic
transmission in response to prolonged electrical
stimulation.8
In this study, we assess the effects of 3 de
novo mutations inDNM1 using cellular assays
and in vivo ultrastrucutral studies in mice.
Collectively, this work provides a possible
mechanistic link between synaptic vesicle traf-
ficking dysfunction and epilepsy.
METHODS Constructs. Wild-type (WT) DNM1 cDNA was
cloned into the pCMV-AC-GFP (OriGene, Rockville, MD) and
pCMV-AC-RFP (OriGene) vectors in frame. Mutagenesis was
performed on green fluorescent protein (GFP)-tagged DNM1 by
site-directed mutagenesis using the NEB Q5 site-directed
mutagenesis kit to create the c.529G.C (A177P), c.618G.C
(K206N), and c.1076G.C (G359A) mutations according to the
manufacturer’s protocol. Plasmid sequences were verified by Sanger
sequencing.
Transferrin assay. COS-7 or HeLa cells were transfected on
Mattek glass bottom plates with the DNM1 constructs using Lip-
ofectamine LTX and PLUS reagent (Life Technologies, Grand Island,
NY) according to the manufacturer’s protocol. Twenty-four hours
after transfection, the assay was performed with AlexaFluor-594–
conjugated transferrin (Life Technologies), as previously described.8
Cells were mounted in VectaShield with 4’,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories, Burlingame, CA) and
imaged with a Zeiss Axio Observer with a 633, 1.4 oil immersion
objective. Exposure times were adjusted for the GFP channel to better
illustrate localization patterns. The experiment was repeated 3 times
with identical conditions.
High-content imaging. HeLa cells were transfected on Poly-D-
Lysine–coated 24-well plates. The transferrin assay was performed as
described. Using a Thermo Scientific Arrayscan VTI, cells were filtered
for positive DAPI andGFP expression. To quantify transferrin uptake,
AlexaFluor-594 (conjugated transferrin fluorophore) intensity was
measured for each positively transfected cell. An average of 5,100
cells were analyzed per well. Spot identification was used to quantify
the number of puncta per cell. Standardized evaluation was performed
by applying the same parameters to each experimental condition.
Downstream quantitative analysis was blinded.
Colocalization. HeLa cells were cotransfected with red fluorescent
protein (RFP)-tagged WT DNM1 and each of the GFP-tagged
mutants on a 12-well Mattek glass bottom plate using Lipofectamine
LTX with PLUS (Life Technologies). Twenty-four hours after
transfection, cells were washed 3 times with ice-cold phosphate-
buffered saline and fixed in 4% paraformaldehyde for 10 minutes at
room temperature. Cells were mounted in VectaShield with DAPI
(Vector Laboratories) and imaged with a Zeiss Axio Observer with a
633, 1.4 oil immersion objective.
Western blot. Monomer expression assay. HeLa cells were
transfected with the DNM1 constructs. Twenty-four hours
after transfection, cells were lysed in 200 mL of radioimmuno-
precipitation assay (RIPA) buffer. The lysates were loaded on a
4%–12% NuPAGE Bis-Tris gel and transferred to a PVDF
membrane. The blots were blocked in 1% casein solution and
then probed with an anti-tGFP antibody (OriGene) at a 1:2,000
dilution overnight at 4°C. The membranes were washed 3 times
with 0.1% Tris-buffered saline (TBS)-Tween. They were then
probed with IRDye 800CW anti-mouse antibody (LI-COR,
Lincoln, NE) at a 1:2,000 dilution for 1 hour at room temper-
ature. The membranes were again washed 3 times in 0.1% TBS-
Tween and imaged. Densitometry was performed using ImageJ,
and downstream quantification was performed using a blinded
analysis.
Cross-linking assay. HeLa cells were transfected as described
above. Twenty-four hours after transfection, the cells were lysed
in RIPA buffer and treated with 20 mM 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) for 45 minutes at
4°C. The Western blot was then performed as described for the
monomer expression assay.
HeLa cell electron microscopy. HeLa cells were transfected
withWT andmutant constructs using Lipofectamine LTX on aMilli-
pore 4-chamber Millicell EZ slide according to the manufacturer’s
protocol (Life Technologies). Twenty-four hours after transfection,
the cells were fixed in 4% glutaraldehyde in borate buffer,
dehydrated, and embedded. Images were acquired on a Phillips CM12.
Mice. C57BL/6J-Dnm1Ftfl mice arose at The Jackson Laboratory
(Bar Harbor, ME) as a spontaneous mutation on the C57BL/6J
inbred strain in 2000.8 All mice were housed and procedures per-
formed with approval of Institutional Animal Care and Use Commit-
tee. All mice were obtained from The Jackson Laboratory, maintained
in a room with a 14-hour light on/10-hour light off cycle, and given
free access to LabChow meal and water.
Brain section electron microscopy. For electron microscopy
(EM), littermate C57BL/6J-Dnm1Ftfl/Ftfl and C57BL/6J-
Dnm11/1 mice (aged 2 weeks) were perfused transcardially
with 2% paraformaldehyde-2% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH 7.4), and the brains were removed and
postfixed overnight at 4°C. Samples were postfixed with 1% OsO4
in 0.1 M cacodylate buffer, dehydrated, and embedded. Grids were
scanned on a JEOL 1230 Transmission Electron Microscope, and
measurements were performed with ImageJ software. For synaptic
vesicle diameter and number analysis, a minimum of 710 vesicles
from each sample was measured. Synaptic vesicle number was
normalized to the area of each synapse measured.
RESULTS We examined a total of 3 de novo mis-
sense mutations in DNM1 (NM_001005336.1)
c.529G.C (p.(Ala177Pro)) (patient 1), c.618G.C
(p.(Lys206Asn)) (patient 2), and c.1076G.C
(p.(Gly359Ala)) (patient 3). Two amino acid substi-
tutions (A177P and K206N) appear in the G domain
of DNM1 and the third substitution (G359A) occurs
in the middle domain (figure 1A). Clinical features of
the probands harboring variants in DNM1 have been
reported.15 All 3 patients had infantile spasms with
onset between 2 and 7 months, later evolving into
LGS. In addition, each patient presented with severe
intellectual disability, pronounced hypotonia, and
absence of speech. Patients 1 and 2 are therapy resis-
tant, while patient 3 has been seizure free since begin-
ning a ketogenic diet at age 3. In addition, patient
1 was diagnosed with autism spectrum disorder.
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Available in silico algorithms predict that all 3 mis-
sense mutations are likely highly damaging to the en-
coded DNM1 protein (PolyPhen-2 score 5 1.00;
SIFT score 5 0).16,17 In addition, DNM1 is among
the 20% of genes that are the most intolerant of func-
tional genetic variation in the human population.18
The A177P mutation occurs at the C-terminus of
b-pleated sheet b4G. The K206Nmutation substitutes
a charged amide residue for a neutral residue at the
C-terminus of b-pleated sheet b5G. The G359Amuta-
tion occurs at the N-terminus of a helix a1Ms (figure
1B). The GERP11 scores at these 3 missense posi-
tions (5.42, 4.41, and 5.88, respectively) are much
higher than the average DNM1 GERP11 score of
3.77, indicating that these sites are highly conserved
relative to the overall conservation of the gene.
Dynamin plays a crucial role in the catalysis of
clathrin-mediated endocytosis. To determine whether
these mutations affect endocytosis, we transfected
COS-7 cells with GFP-tagged DNM1 constructs and
measured effects on uptake of fluorescently labeled trans-
ferrin. Cells containing WT-transfected DNM1 showed
a perinuclear accumulation of the fluorescently labeled
transferrin (figure 2A). However, overexpression of the
G-domain mutants, A177P and K206N, significantly
inhibited transferrin uptake (figure 2, B and C). The
middle-domain mutation, G359A, showed some trans-
ferrin uptake in occasional cells but was largely inhibited
(figure 2D). In addition to their effects on endocytosis,
the mutant DNM1 proteins exhibited different patterns
of localization. WT DNM1 formed distinct, round
puncta (figure 2A), while the A177P mutant had a dif-
fuse cytosolic distribution accompanied by puncta
(figure 2B). The K206N mutant exhibited abnormally
large protein aggregates with a nonuniform distribution
throughout the cell (figure 2C). Finally, the G359A
mutant dynamin lacked puncta and exhibited a reticular
distribution throughout the cell (figure 2D).
To quantify differences in endocytosis levels and
localization ofDNM1, we performed high-content imag-
ing analyses on transfected HeLa cells. First, intensity of
the transferrin fluorophore was measured in positively
transfected cells. Compared to cells transfected with the
WT DNM1 construct, overexpression of each mutant
protein conferred nearly a 60% reduction in transferrin
uptake (figure 3A). Spot identification analysis was used
to quantify differences in puncta per cell and revealed a
50% reduction in the number of puncta in the G359A
mutant (figure 3B).
Because DNM1 is the predominant dynamin in neu-
rons,19 we were interested to see whether the mutant
forms of the protein could colocalize with WT
DNM1. To test this hypothesis, RFP-tagged WT
DNM1 was cotransfected with each of the GFP-tagged
mutants. Each mutant protein significantly colocalized
with WT DNM1, suggesting likely interaction between
the WT and mutant proteins (figure e-1 at Neurology.
org/ng). Additionally, in contrast to the aberrant locali-
zation patterns when transfected alone, all 3 mutant
proteins formed puncta in the presence of WT DNM1.
Figure 1 DNM1 mutations and structure
(A) Structure-based domain architecture of human DNM1. The A177P and K206Nmutations occur in the G domain and the
G359A mutation occurs in the middle domain. The location of the mouse Dnm1Ftfl (A408T) mutation is indicated above the
middle domain. (B) Positions of the amino acid substitutions in the DNM1 crystal structure, shown as a ribbon-type
representation.
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Because these mutations were predicted to be
highly damaging to functional DNM1, we performed
aWestern blot on transfectedHeLa cells to assay possible
differences in expression levels (figure 4A). Average nor-
malizedWT andmutant DNM1 levels were determined
and are shown in figure 4B. The K206Nmutant protein
showed a 75%decrease in steady-state levels compared to
WT. It is interesting that the G359A transfected cells
showed nearly a 2-fold increase in expression.
We next conducted a cross-linking assay to test
whether the mutations disrupt DNM1 protein
dimerization. We suspected that mutant G359A would
disrupt dimerization, as the middle domain is involved
in dynamin self-assembly, as shown previously for the
mouse Dnm1Ftfl mutation.8 Forty-eight hours after
transfecting HeLa cells with mutant constructs, cell
lysates were treated with 20 mM EDC, a zero-length
cross-linking agent, and analyzed by Western blot with
Figure 2 DNM1 mutations inhibit transferrin uptake
Inhibition of transferrin internalization in mammalian cell lines. COS-7 cells were transfected with green fluorescent protein
(GFP)-tagged DNM1 constructs and then treated with fluorescently labeled transferrin. Scale bar, 20 mm. (A) Cells express-
ing wild type (WT)DNM1 exhibit transferrin uptake with a perinuclear accumulation. WT DNM1 forms round puncta that are
evenly dispersed throughout the perimeter of the cell. (B) The A177Pmutant inhibits transferrin uptake.DNM1 shows some
diffuse GFP signal throughout the cytosol accompanied by puncta. (C) The K206N mutant also inhibits transferrin uptake
and shows abnormal aggregation of DNM1. (D) The G359Amutant shows some transferrin uptake in certain cells. There is a
distinct lack of puncta, and DNM1 shows a reticular GFP signal throughout the cytosol.
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anti-GFP antibody. The relative levels of monomer and
dimer are shown in figure 4C. The G-domain mu-
tants showed similar dimerization patterns to WT, but
the G359A middle-domain mutant was associated with
nearly a 50% decrease in dimerization, consistent with
the Dnm1Ftfl result.
During endocytosis, DNM1 pinches forming
vesicles from the plasma membrane. We conducted
EM on transfected HeLa cells to determine effects
of the mutants on vesicle scission. In cells transfected
with the A177P construct, we observed extremely
large abnormally shaped vesicles and smaller vesicles
that clustered at the edge of the plasma membrane
(figure 5A). This finding supports our hypothesis that
G-domain DNM1 mutations significantly affect
vesicle formation. Previously reported dominant-
negative G-domain DNM1 mutants exhibited deep
clathrin-coated invaginations in the membrane by
EM,14 but while we observed this phenotype in the
G359A construct by immunofluorescence, we were
not able to detect it by EM for these mutations. In
contrast, in cells transfected with the G359A mutant
construct, there were no obvious vesicle abnormalities
(figure 5A).
Because the previously reported Dnm1Ftfl muta-
tion (figure 1A) results in an early-onset seizure dis-
order in the mouse, decreases endocytosis activity in
heterologous expression assays, and decreases oligo-
merization of DNM1,8 we reasoned that this muta-
tion acts as a good model of the 3 human mutations.
To understand the effects of DNM1 mutations on
vesicle trafficking in vivo, we conducted EM on brain
sections of the Dnm1Ftfl mouse. Overall, we observed
a significant general decrease in vesicle number and
an increase in vesicle size in synapses from both hip-
pocampal and cortical regions when compared with
WT (figure 5, B–D). Together, these findings suggest
a stall in the overall fission activity of mutant DNM1,
resulting in larger and fewer vesicles indicative of
defects in endocytosis.
DISCUSSION In this study, we analyzed the func-
tional consequences of 3 de novo DNM1 missense
mutations that were identified among patients with
LGS, a severe epileptic encephalopathy. When expressed
alone in COS-7 and HeLa cells, all 3 mutant constructs
significantly inhibited endocytosis. Cells that overexpress
WT DNM1 do not show an increase in overall
transferrin uptake compared to cells transfected with a
control GFP construct. Thus, the significant decrease in
transferrin uptake suggests a dominant-negative effect of
all 3 mutations, consistent with several other reported
DNM1mutations.14 Furthermore, mammalian genomes
contain a total of 3 dynamin genes: DNM1, DNM2,
and DNM3.20 DNM2 is expressed ubiquitously,21
while DNM3 is expressed in the brain and the testes.4
Given the ubiquitous expression of DNM2, the
profound inhibitory effect on endocytosis suggests
that the mutant DNM1 proteins bind to
endogenous DNM2, thus interrupting DNM2
function and causing an accumulation of endocytotic
intermediates.4,8
Both G-domain mutant proteins, A177P and
K206N, showed different localization patterns from
WT when expressed alone. EM revealed dramatic
vesicle abnormalities, and our Western blot results
indicate that neither mutation affects dimerization,
but there is a significant decrease in steady-state levels
of the K206N mutant, possibly suggesting decreased
stability of this protein. Our co-transfection studies
indicate that both mutant proteins colocalize—and
presumably dimerize—with WT DNM1. We hypoth-
esize that these mutations decrease GTP hydrolysis in a
fashion similar to that reported for other dominant-
negative G-domain mutants.2,14,22 Because GTP
hydrolysis is necessary for vesicle scission,14 disruptions
Figure 3 Quantification of transferrin uptake
and cellular localization patterns
(A) High-content imaging analysis of transferrin fluorophore
intensity in positively transfected HeLa cells. All 3 muta-
tions confer nearly a 60% reduction in transferrin uptake
compared to wild type (WT). Error bars represent SD
between 5 replicate wells. p , 0.05 by Student t test. (B)
High-content imaging spot identification revealed a 50%
reduction in the number of puncta in cells expressing the
G359A mutation. Error bars represent SD among 5 repli-
cate wells. *p , 0.05 by Student t test.
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to this process likely lead to the observed decreased
endocytosis activity.
The middle-domain mutation, G359A, also affected
DNM1 localization. It is interesting that this mutant pro-
tein exhibited a reticular, or tube-like, distribution corre-
lating with the transferrin signal. This is highly similar to
what is observed when the Dnm1-Ftfl protein is overex-
pressed in COS-7 cells.8 Other studies of dominant-
negative DNM1-expressing cells have reported reticular
localization of some mutants, proposing that mutant
dynamin can assemble on and tubulate the membrane
but cannot function to fission the membrane, thus
resulting in a longer lifetime on the membrane than
WT dynamin.14
The middle-domain mutation interfered with
DNM1 dimerization and showed nearly a 2-fold
increase in monomer expression compared to WT.
Since each of these proteins is expressed from cDNA
constructs with constitutive cytomegalovirus
promoters, these observations suggest different stabil-
ities of the WT and mutant proteins. However, it is
unclear why the monomeric form is more stable. Mem-
brane invagination and fission are mediated by 2 separate
dynamin mechanisms that require both assembly-
independent and assembly-dependent GTPase
activity.23,24 Thus, we hypothesize that an increase
in the monomeric form of this mutant protein may
allow it to bind to and sequester certain interacting ves-
icle trafficking partners to achieve its dominant-negative
effect. It is interesting that cells expressing the G359A
mutant protein did not show the same vesicle defects as
cells transfected with the G-domain mutant constructs
in EM. As previously hypothesized for the mouse fitful
mutation, which also occurs in the middle domain, we
believe that the G359A mutant would not participate in
assembly-stimulated activity required for vesicle scission
but would retain the assembly-independent activity
required for membrane invagination.8
The G359A and Dnm1Ftfl constructs produce the
same cellular phenotype when expressed in COS-7
cells: decreased transferrin endocytosis, a reticular
DNM1 distribution, and decreased dimerization.
Thus, the Dnm1Ftfl mutation is a very good model
for this mutation. Our EM data from Dnm1Ftfl neu-
rons reveal an overall increase in vesicle size coupled
with a decrease in vesicle number. Because dynamin-
mediated scission is the rate-limiting step of endocy-
tosis,25 these results suggest a stall in the endocytosis
process due to decreased dynamin-mediated mem-
brane fission. Together, these data illustrate that
dominant-negative DNM1 mutations are also likely
to disrupt vesicle trafficking in vivo.
Although they may achieve a dominant-negative
interaction through different mechanisms, each mutant
protein causes endocytosis defects, as suggested by our
transferrin assay. One possible consequence is that
decreased endocytosis activity results in a depleted
pool of synaptic vesicles, as supported by EM of fitful
neurons. It has been previously shown that inhibitory
neurons are more sensitive to the lack of DNM1, pre-
sumably due to their tonic activity.26 Thus, a lack of
synaptic vesicles in inhibitory neurons could cause
decreased GABA transmission, leading to network-
level hyperactivity and an epileptic phenotype. Alterna-
tively, these mutations may affect neurite formation, as
recent evidence illustrates that inhibiting dynamin-
dependent endocytosis disrupts neurite outgrowth.27
Additional neuronal-based studies are required to fully
elucidate the downstream effects of inhibited neuronal
endocytosis.
Our study adds to the increasing evidence that
dysfunctional synaptic vesicle cycling is a mechanism
for neurologic disorders. Mutations in other vesicle
trafficking genes, such as STXBP1, SYN1, and
LRRK2, have been implicated in autism spectrum
Figure 4 DNM1 mutations affect protein levels and self-dimerization
(A) HeLa cells were transfected with green fluorescent protein (GFP)-tagged mutant constructs.
The blotswere probedwith anti-GFP antibodies. A representative blot is shown. (B) Quantification
of protein expression levels from 3 independent Western blot experiments is shown. Actin levels
were used for normalization and error bars indicate SD values. *p , 0.05 by Student t test.
(C) HeLa cell lysates from cells transfected with GFP-tagged mutant constructs were treated
with 20 mM 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) cross-linking agent and ana-
lyzed by Western blot. The monomeric and dimeric forms are indicated. WT 5 wild type.
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disorder, epileptic encephalopathies, and Parkinson
disease.27–29 Together, these studies support the
emerging paradigm in neurology that disruptions in
the same pathway can increase risk for a broad range
of neuropsychiatric disorders.30
Finally, our results emphasize that functional
analysis driven by genomic data can play an impor-
tant role in discovering novel disease mechanisms. A
wide spectrum of proteins, including channel
proteins, protein modifiers, RNA binding proteins,
and others, have been implicated in LGS alone.31
Thus, due to their genetic heterogeneity, treatment
considerations for epileptic encephalopathies will
eventually be guided by the underlying pathogenic
mechanism in any given patient. Further under-
standing of the relation between synaptic vesicle
dysfunction and epilepsy will facilitate the discovery
of treatment opportunities.
Figure 5 Electron microscopy of transfected HeLa cells and Dnm1Ftfl neurons
(A) Electron microscopy (EM) of HeLa cells transfected with wild type (WT) and mutant DNM1 constructs. There are larger
and abnormal vesicles in the A177Pmutant. Cells transfected with the G359A show no obvious vesicle defects. Scale bars,
1 mm. (B) EM of WT mouse brain sections. (C) EM of Dnm1Ftfl mouse neurons reveals increased vesicle size. (D) A box plot
depicting the number of vesicles in both WT and Dnm1Ftfl neurons. Outliers are excluded from the plot. Significance was
determined by theMann-Whitney-Wilcoxon test (**p, 0.005, ***p, 0.0005). (E) A box plot depicting the size of vesicles in
both WT and Dnm1Ftfl neurons. There were significantly larger vesicles in both hippocampal and cortical neurons. Outliers
are excluded from the plot. Significance was determined by the Mann-Whitney-Wilcoxon test.
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